Precision CRISPR: Drug Development & Gene Therapy Congress

Learn more about the future of CRISPR gene editing.

At the Precision CRISPR Congress, we will present our FluidFM BOT system that optimises CRISPR-Cas delivery and the transfection of plasmids.

Perform fast injection of CRISPR-Cas complexes, even into cells difficult to target with conventional CRISPR delivery methods. Using the FluidFM BOT system to deliver your CRISPR-Cas complex, you can selectively choose the cell you want to inject within a cell culture. In addition, deliver your CRISPR-Cas complex directly to where it is required: the nucleus. This is performed without affecting the neighbouring cells.

Transfection of plasmids with FluidFM nanoinjection enables the delivery of genetic material even into difficult to transfect cells and in a faster, and for the cells, less stressful manner than with conventional methods. In contrast to conventional transfection methods, no toxic compounds are necessary to allow the DNA vector to enter the cell. Observe the expression of your plasmid as early as 3h post injection.

The FluidFM BOT system is an unmatched tool to introduce a vast variety of materials of your choice into a cell. From small molecules to proteins, RNAs, and plasmids, the FluidFM nanosyringe can be loaded with – and thus deliver – virtually any kind of liquid-based solution in a cell-context preserving, non-destructive and measurable manner.

The efficiency of the FluidFM nanoinjection has already been demonstrated in various kind of cell types such as HeLa, HEK, CHO or human iPS cells.

Learn more at Precision CRISPR!

About the Congress

The Precision CRISPR Congress supports pharma and biotech community in realising the drug discovery & gene therapy applications of optimised CRISPR systems.
Join the 3rd Precision CRISPR Congress and take part in conversations around the future of CRISPR gene editing in Europe and the rest of the world. Through a dynamic program of focused sessions, interactive discussions and networking opportunities, you will leave the congress with a deep understanding of:

• the challenges in delivery & reducing off-target effects in ex vivo & in vivo gene therapies

• how the likes of GSK, Novartis, AstraZeneca and more, work towards improving the efficacy of functional screening and drug discovery

• the most recent gene editing techniques and Cas variants poised to make precise gene editing all that more precise
  

For more information on the event, please go to the website of Precision CRISPR Congress.